Navigation Links
Meta-analysis shows no heart benefits for folic acid supplements
Date:10/11/2010

Use of folic acid supplements appears to lower blood levels of the amino acid homocysteinetheorized to be a risk factor for heart and blood vessel diseasebut does not appear to be associated with reduced rates of cardiovascular events, cancer or death over a five-year period, according to a meta-analysis of previously published studies in the October 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

"Elevated plasma total homocysteine [an amino acid created by the body, usually as a byproduct of eating meat] has been suggested as a potentially modifiable risk factor for coronary heart disease, stroke and other occlusive vascular conditions," the authors write as background information in the article. High rates of cardiovascular disease in children with homocystinuriaa rare genetic condition causing extreme elevations in homocysteine levelsled researchers to hypothesize that moderate increases in blood homocysteine levels may increase cardiovascular disease risk in the general population.

Supplementation with B vitamins, and in particular folic acid, lowers blood homocysteine levels and reduces cardiovascular disease risk among individuals with homocystinuria. Several large clinical trials conducted in patients without the condition have been inconclusive. "Consequently, a collaboration between their investigators was established in 2004 to conduct a meta-analysis based on individual participant data from all large randomized trials of folic acidbased B-vitamin supplementation intended to lower plasma homocysteine levels for the prevention of cardiovascular disease," the authors write.

Robert Clarke, F.R.C.P., University of Oxford, England, and colleagues in the B-Vitamin Treatment Trialists' Collaboration report the results of the meta-analysis of all eight trials completed by the end of 2009. Of a total of 37,485 participants, 18,723 were assigned to take folic acid in doses ranging from 0.8 millig
'/>"/>

Contact: Robert Clarke, F.R.C.P.
robert.clarke@ctsu.ox.ac.uk
JAMA and Archives Journals
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Meta-analysis: Radiotherapy variants improve survival in non-metastatic lung cancer
2. Investigational ovarian cancer drug shows promise against platinum resistant disease
3. New study shows benefits of Bt corn to farmers
4. T cell discovery shows promise for Type 1 diabetes treatment: UBC-CFRI study
5. 1st census shows life in planet ocean is richer, more connected, more altered than expected
6. New USDA study shows extent of land degradation and recovery on western rangelands
7. Study shows real partners are no match for ideal mate
8. In-country OB/GYN training programs contributed to retention of doctors in Ghana, U-M study shows
9. Garlic oil shows protective effect against heart disease in diabetes
10. New study shows over one-fifth of the worlds plants are under threat of extinction
11. Nature Nanotechnology paper shows enzyme-controlled movement of DNA polymer through a nanopore
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/7/2015)... Research and Markets ... the "Capacitive Fingerprint Sensors Patent Landscape" ... date, fingerprint sensing technology is the most reliable ... well developed. This patent landscape focuses on fingerprint ... domain of capacitive fingerprint sensors is closely linked ...
(Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... sound counterintuitive, but LSU Associate Professor of Chemistry Robert Cook ... materials found in the environment, including soils, can either get ... or NSF, was so impressed with his efforts that the ... the NSF CAREER award. "One of the biggest questions ...
... You can teach an old drug new chemotherapy tricks. ... blood cancers but ineffective against solid tumors, packaged it ... type of breast cancer prevalent in young women, particularly ... trioxide, long part of the arsenal of ancient Chinese ...
... Eurofins MWG Operon, an expert in next generation sequencing ... capture, together with Genomatix Software GmbH, a leading company ... announce that they have developed a complete human exome ... "We are pleased to offer this comprehensive service for ...
Cached Biology News:LSU researcher looks for new ways to keep a dirty situation clean 2LSU researcher looks for new ways to keep a dirty situation clean 3New arsenic nanoparticle blocks aggressive breast cancer 2New arsenic nanoparticle blocks aggressive breast cancer 3Eurofins MWG Operon and Genomatix developed most complete human exome array 2
(Date:7/30/2015)... -- HIGHLIGHTS:Q2 2015 Results (all changes are ... sales were $697 million compared to $701 million in ... 8%, and changes in foreign currency exchange rates decreased ... , By business unit, organic sales growth was ... SAFC Commercial. , Reported diluted EPS was $0.98 ...
(Date:7/29/2015)... July 30, 2015 Sanofi, ... for the second quarter of 2015. CEO ... and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in ... - Performance drivers - ...
(Date:7/29/2015)... / Japan (Q2 2015: +14% CER / ... on high-single-digit growth in China , as well as solid ... . Europe / Middle East ... sales) showed gains in Germany , Turkey ... +4% CER / 49% of sales) grew 11%, excluding U.S. HPV sales, on ...
(Date:7/29/2015)... ... July 29, 2015 , ... G-CON Manufacturing, ... launch of their 2nd generation cell therapy POD® design. The 2nd generation portfolio ... also represents a new POD® design. , “G-CON first offered our miniPOD ...
Breaking Biology Technology:Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3
... LASIK Surgeons directory service and website at www.TrustedLASIKSurgeons.com ... seeking to improve their vision. What sets the Trusted ... ensuring that only those who are among the best ... the United States are listed. Refractive eye surgeons, such ...
... their retina cells or other tissues can be tracked ... computer record of movement and gene expression. The new ... Biotechnology , will allow detailed analyses of correlations between ... a team of researchers from the University of Southern ...
... for Equipment and Service Excellence at the 54th Annual ... , IRVINE, Calif., Dec. 16 Masimo ... CO-Oximetry and Measure-Through-Motion and Low-Perfusion pulse oximetry, announced that ... notification system, Masimo Patient SafetyNet, was featured in a ...
Cached Biology Technology:Hawaii LASIK Eye Surgery Expert Dr. John D. Olkowski Qualifies and Lists with Trusted LASIK Surgeons 2Hawaii LASIK Eye Surgery Expert Dr. John D. Olkowski Qualifies and Lists with Trusted LASIK Surgeons 3Hawaii LASIK Eye Surgery Expert Dr. John D. Olkowski Qualifies and Lists with Trusted LASIK Surgeons 4Hawaii LASIK Eye Surgery Expert Dr. John D. Olkowski Qualifies and Lists with Trusted LASIK Surgeons 5Hawaii LASIK Eye Surgery Expert Dr. John D. Olkowski Qualifies and Lists with Trusted LASIK Surgeons 6Hawaii LASIK Eye Surgery Expert Dr. John D. Olkowski Qualifies and Lists with Trusted LASIK Surgeons 7AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities 2AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities 3AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities 4AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities 5
Rat monoclonal [HK5.3] to B7 RP1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
In plasmid or lambda vector. Please inquire for more details!...
Anti-Mouse D011.10 TCR, Biotin (Clone KJ1-26) (mouse IgG2a)...
Rabbit monoclonal [E227] to ZAP70 (phospho Y319) ( Abpromise for all tested applications). Antigen: Synthetic phospho peptide corresponding to residues surrounding Tyr319 of human ZAP70 Entre...
Biology Products: